Risk of heart failure in elderly patients with atrial fibrillation and diabetes taking different oral anticoagulants: a nationwide cohort study

Table 2 Risk of heart failure in older patients with atrial fibrillation and diabetes receiving NOAC versus warfarin

	Event no	Person-years	Incidence rate^†	HR (95% CI)	p-value
Fine stratification weights estimating ATE^*
NOAC (N = 19,591)	4512	59,298	76.1	0.80 (0.74–0.86)	< 0.001
Warfarin (N = 5,117)	1404	14,677	95.6	1 (ref.)	< 0.001
Fine stratification weights estimating ATT^**
NOAC (N = 19,591)	4158	55,059	75.5	0.77 (0.70–0.84)	< 0.001
Warfarin (N = 5,117)	1343	13,576	98.9	1 (ref.)	< 0.001

ATE average treatment effect in the whole population, ATT average treatment effect among the treated population, CI confidence interval, HR hazard ratio, NOAC non-vitamin K antagonist oral anticoagulant, ref. reference
^*Propensity score-based fine stratification weighting which estimated the average treatment effect in the whole population
^**Propensity score-based fine stratification weighting which estimated the average treatment effect among the treated population
^†Incidence rate, per 1000 person-years

ISSN: 1475-2840